Compare SQM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQM | INSM |
|---|---|---|
| Founded | 1968 | 1988 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9B | 22.4B |
| IPO Year | 1997 | 2000 |
| Metric | SQM | INSM |
|---|---|---|
| Price | $74.15 | $124.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 24 |
| Target Price | $68.80 | ★ $201.17 |
| AVG Volume (30 Days) | 897.5K | ★ 3.1M |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $182.31 |
| Revenue Next Year | $7.83 | $65.19 |
| P/E Ratio | $39.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.58 | $90.39 |
| 52 Week High | $98.00 | $212.75 |
| Indicator | SQM | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 58.12 | 59.82 |
| Support Level | $68.80 | $95.24 |
| Resistance Level | $75.74 | $140.30 |
| Average True Range (ATR) | 2.02 | 4.84 |
| MACD | 0.83 | 2.21 |
| Stochastic Oscillator | 95.71 | 66.69 |
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM also sells lithium concentrate from a joint venture hard rock lithium project in Australia and expanding its lithium refining assets in China.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.